Telix Pharmaceuticals (TLX) Doses First Patient in Phase 3 Trial for Brain Cancer Therapy

2 hours ago 1

Maham Fatima

Sun, April 19, 2026 astatine 10:44 AM CDT 2 min read

Telix Pharmaceuticals Limited (NASDAQ:TLX) is 1 of the

10 Overlooked Growth Stocks to Buy Now. Telix Pharmaceuticals Limited (NASDAQ:TLX) is 1 of the overlooked maturation stocks to bargain now. On April 14, Telix Pharmaceuticals announced the dosing of the archetypal diligent successful its pivotal Phase 3 IPAX-BrIGHT trial. This marks a historical milestone arsenic the archetypal radiopharmaceutical therapy to scope Phase 3 improvement for recurrent glioblastoma, a highly assertive and difficult-to-treat signifier of encephalon cancer. The proceedings is evaluating the information and efficacy of TLX101-Tx (¹³¹I-iodofalan) successful operation with the chemotherapy cause lomustine, compared to chemotherapy alone. The attraction uses a caller small-molecule attack to people the L-type amino acerb transporter 1 (LAT1). Because LAT1 is overexpressed successful glioblastoma cells, the radiopharmaceutical tin successfully transverse the blood-brain obstruction to present targeted radiation straight to the tumor site. This mechanics is peculiarly important fixed that lone 2 drugs person been FDA-approved for glioblastoma successful the past 25 years, and determination is presently nary established modular of attraction for patients erstwhile the illness recurs. The Phase 3 survey builds connected encouraging information from earlier trials, specified arsenic IPAX-1, which showed a median wide endurance of 13 months from the commencement of treatment. In the IPAX-BrIGHT trial, Telix’s companion PET imaging agent, TLX101-Px, volition beryllium utilized to prime eligible patients and show their metabolic effect to the therapy. With regulatory approvals already secured successful Australia and respective European nations, Telix Pharmaceuticals Limited (NASDAQ:TLX) aims for this registration-enabling survey to found a first-in-class therapy for a diligent colonisation with precise constricted options.

Telix Pharmaceuticals (TLX) Doses First Patient successful Phase 3 Trial for Brain Cancer Therapy

Telix Pharmaceuticals Limited (NASDAQ:TLX) is simply a biopharma institution that specializes successful therapeutic and diagnostic radiopharmaceuticals and associated aesculapian technologies. The institution develops objective and commercial-stage products to code unmet aesculapian needs successful oncology and uncommon diseases. While we admit the imaginable of TLX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock. READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article